Pure Bioscience (PURE) AI Stock Analysis

• Market Cap: $6.71M
• Dividend Yield: N/A
• Average Volume (3M): 53.72K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.60
• Revenue Growth: 12.18%
• EPS Growth: 28.67%
• Country: US
• Employees: 11
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): >-0.01
• Shares Outstanding: 111,886,475
• 10 Day Avg. Volume: 24,352
• 30 Day Avg. Volume: 53,720
• PEG Ratio: <0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00456
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 1.64
• Enterprise Value/Revenue: 5.76
• Enterprise Value/Gross Profit: 9.92
• Enterprise Value/Ebitda: -4.37
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 34 Underperform
• Price Target: ―

Pure Bioscience's overall stock score is low due to severe financial instability, marked by declining revenues and persistent losses. Technical analysis confirms a bearish trend, with all major moving averages indicating downward momentum. Valuation metrics, such as a negative P/E ratio and lack of dividends, further undermine the stock's attractiveness. Immediate strategic and operational improvements are crucial for any potential turnaround.

Positive Factors

Product Innovation

Pure Bioscience's innovative SDC technology offers a competitive edge in antimicrobial solutions, supporting long-term growth in health and safety sectors.

Market Opportunities

By focusing on high-demand sectors, Pure Bioscience is well-positioned to capitalize on growing needs for effective antimicrobial solutions, enhancing revenue potential.

Strategic Partnerships

Strategic partnerships expand market reach and application scope, fostering sustainable revenue streams and strengthening market position.

Negative Factors

Financial Instability

Financial instability, marked by declining revenues and negative equity, threatens long-term viability and limits growth opportunities.

Negative Cash Flow

Ongoing negative cash flow indicates challenges in maintaining liquidity and self-financing operations, impacting financial health.

Revenue Decline

Significant revenue decline suggests weakening market position and operational inefficiencies, posing risks to long-term growth.

Pure Bioscience Business Overview & Revenue Model

Company Description

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

How the Company Makes Money

Pure Bioscience generates revenue through the sale of its proprietary antimicrobial solutions, primarily its Silver Dihydrogen Citrate (SDC) technology. The company targets multiple industries, such as food processing, healthcare, and consumer goods, where there is a high demand for effective and safe antimicrobial agents. Key revenue streams include direct sales to end-users, partnerships with distributors and manufacturers who incorporate SDC into their products, and licensing agreements where third parties pay for the right to use SDC technology in their own offerings. Significant partnerships with companies in the food safety and healthcare sectors bolster its earnings by expanding its market reach and application scope.

Pure Bioscience Financial Statement Overview

Summary

Pure Bioscience is facing significant financial challenges across income, balance sheet, and cash flow statements. The company shows declining revenues, persistent losses, and a deteriorating balance sheet with negative equity and high leverage. Cash flow remains weak, further complicating its financial stability. Immediate strategic interventions are essential to revitalizing its financial health and operational efficiencies.

Income Statement

Pure Bioscience shows a declining revenue trend from 2020 to TTM 2025, with revenue dropping significantly from $6.9M in 2020 to $1.9M in the latest TTM period. Gross profit margins have deteriorated from 58.1% in 2020 to 58.3% in TTM 2025. Net profit margins have been consistently negative, highlighting ongoing losses. The company faces challenges in achieving positive EBIT and EBITDA, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity and rising total debt, reaching $3.98M in TTM 2025. The debt-to-equity ratio is undefined due to negative equity, and the equity ratio is negative, reflecting substantial financial instability. The company's liabilities exceed its assets, indicating potential solvency issues.

Cash Flow

Pure Bioscience is experiencing persistent negative free cash flow, with minimal improvement in operating cash flow. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting sales into cash flow. The free cash flow is negative, indicating ongoing struggles in maintaining liquidity and self-financing operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.91M	2.20B	1.96M	1.88M	1.85M	3.93M
Gross Profit	1.11M	1.30B	1.15M	971.00K	1.00M	2.08M
EBITDA	-2.52M	-2.27B	-3.05M	-3.83M	-3.27M	-2.14M
Net Income	-2.82M	-2.40B	-3.35M	-3.96M	-3.50M	-2.32M
Balance Sheet
Total Assets	1.06M	1.06B	818.00K	1.82M	4.48M	4.30M
Cash, Cash Equivalents and Short-Term Investments	540.00K	334.00M	349.00K	1.09M	3.39M	2.39M
Total Debt	4.90M	5.24B	2.95M	1.02M	0.00	239.00K
Total Liabilities	5.87M	6.17B	3.68M	1.55M	575.00K	970.00K
Stockholders Equity	-4.81M	-5.12B	-2.86M	272.00K	3.91M	3.33M
Cash Flow
Free Cash Flow	-2.15M	-2.02B	-2.53M	-3.31M	-2.50M	-1.69M
Operating Cash Flow	-2.15M	-2.02B	-2.53M	-3.28M	-2.42M	-1.17M
Investing Cash Flow	0.00	0.00	0.00	-33.00K	-81.00K	-521.00K
Financing Cash Flow	2.25M	2.00B	1.78M	1.01M	3.50M	239.00K

Pure Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PURE, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.78 is Neutral, neither overbought nor oversold. The STOCH value of 61.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PURE.

Pure Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UG	71 Outperform	$32.48M	12.70	17.85%	10.40%	-18.29%	-43.76%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
TANH	55 Neutral	$1.74M	-0.14	―	―	-9.25%	-109.49%
MTEX	50 Neutral	$18.44M	―	-19.54%	―	-9.17%	-4.64%
TKLF	48 Neutral	$13.84M	2.21	16.79%	―	7.75%	-21.61%
GROV	47 Neutral	$56.70M	-2.13	-130.15%	―	-15.42%	7.12%
PURE	34 Underperform	$6.71M	-2.80	127.81%	―	12.18%	28.67%